Endocrinology

Top Story

FDA: Long-term safety, efficacy data added to Saxenda product label

April 27, 2017

The FDA today approved an updated product label for liraglutide injection 3 mg to include long-term safety and efficacy data from the 3-year SCALE Obesity and Prediabetes trial, according to a press release from Novo Nordisk.

The SCALE trial investigated the long-term efficacy and safety of liraglutide (Saxenda, Novo Nordisk) in combination with a reduced-calorie meal plan and increased physical activity in adults with obesity or excess weight and at least one weight related comorbidity. Participants were assigned to liraglutide or placebo, and more participants assigned to liraglutide who lost 5% or more of their weight after 56 weeks (26% vs. 10% on placebo) were able to maintain the weight loss at 3 years (56% vs. 25%).

In the Journals Plus

Obesity, central obesity increase precocious puberty risk

April 27, 2017
The risk for precocious puberty may be increased with childhood obesity and/or central obesity; the risk is more pronounced in girls than boys, according to findings…
In the Journals Plus

VTE in women may suggest inappropriate prescriptions of combined hormonal contraceptives

April 26, 2017
Women assigned combined hormonal contraceptives who experience a venous thromboembolism may have vascular contraindications suggesting inappropriate prescriptions…
In the Journals Plus

Type 2 diabetes increases risk for dementia conversion in patients with mild cognitive impairment

April 26, 2017
Adults with type 1 diabetes and mild cognitive impairment are twice as likely to develop dementia as those who have mild cognitive impairment without diabetes, according…
In the Journals Plus

Diabetes risk high in Filipino Americans without obesity

April 26, 2017
Compared with non-Hispanic white adults, American adults of Filipino descent face higher risk for diabetes at a nonobese BMI, according to findings published in the…
More News Headlines »
CME

Improving Bone Strength and Reducing Fracture Risk in Osteoporosis

This activity is supported by an educational grant from Merck & Co., Inc.

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue leading to reduced…
More »
Video
Meeting News

VIDEO: Bone screens still necessary in type 2 diabetes despite normal, high BMD

April 3, 2017
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME CNE CE CE

Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Current Issues
View the Current Issues
Advertisement
Advertisement